Literature DB >> 26162642

First Isolation of Azole-Resistant Cryptococcus neoformans from Feline Cryptococcosis.

Rui Kano1, Miki Okubo2, Tokuma Yanai3, Atsuhiko Hasegawa4, Hiroshi Kamata2.   

Abstract

We report here, to the best of our knowledge, the first description of an in vitro fluconazole (FLZ)-resistant Cryptococcus neoformans var. grubii from a case of feline cryptococcosis. In vitro testing demonstrated that this isolate was resistant to FLZ (minimum inhibitory concentration, MIC, of 128 μg/ml) but remained susceptible to amphotericin B (0.064 µg/ml), itraconazole (0.38 µg/ml), voriconazole (0.023 µg/ml), and posaconazole (0.125 µg/ml). The predicted amino acid sequence of the lanosterol 14-α demethylase (ERG11) protein in the isolate was identical to that of the C. neoformans var. grubii reference strain, indicating that resistance was not mediated by mutation of the target gene's open reading frame. The RT-qPCR analysis for ERG11 and ATP-binding cassette (ABC) transporter-encoding gene (AFR1) indicated that the isolate increased transcription factor function of ERG11 and AFR1 than that of FLZ-susceptive strains. This observation, in combination with the lack of resistance to other azoles (that is, lack of crossresistance), suggests that resistance in our isolate was the result of overexpression of the endogenous ERG11 and ABC transporter.

Entities:  

Keywords:  Azole; Cryptococcosis; Feline; Fluconazole; In vitro susceptibility test; Resistance

Mesh:

Substances:

Year:  2015        PMID: 26162642     DOI: 10.1007/s11046-015-9919-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  9 in total

1.  G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

Authors:  Laura Rodero; Emilia Mellado; A Carolina Rodriguez; Angela Salve; Liliana Guelfand; Pedro Cahn; Manuel Cuenca-Estrella; Graciela Davel; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  A case of feline cryptococcosis treated with itraconazole.

Authors:  R Kano; Y Nakamura; T Watari; H Tsujimoto; A Hasegawa
Journal:  Mycoses       Date:  1997-12       Impact factor: 4.377

3.  Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Marilena La Sorda; Riccardo Torelli; Barbara Fiori; Rosaria Santangelo; Giovanni Delogu; Giovanni Fadda
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

4.  PCR detection of the Cryptococcus neoformans CAPS9 gene from a biopsy specimen from a case of feline cryptococcosis.

Authors:  R Kano; Y Fujino; N Takamoto; H Tsujimoto; A Hasegawa
Journal:  J Vet Diagn Invest       Date:  2001-09       Impact factor: 1.279

5.  Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  J L Lopez-Ribot; R K McAtee; L N Lee; W R Kirkpatrick; T C White; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

6.  Serotypes and mating types of clinical isolates from feline cryptococcosis in Japan.

Authors:  Ken Okabayashi; Rui Kano; Toshi Watanabe; Atsuhiko Hasegawa
Journal:  J Vet Med Sci       Date:  2006-01       Impact factor: 1.267

Review 7.  Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.

Authors:  F P Gullo; S A Rossi; J de C O Sardi; V L I Teodoro; M J S Mendes-Giannini; A M Fusco-Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

8.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A I Aller; E Canton; L R Castañón-Olivares; A Chowdhary; S Cordoba; M Cuenca-Estrella; A Fothergill; J Fuller; N Govender; F Hagen; M T Illnait-Zaragozi; E Johnson; S Kidd; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; G St-Germain; L Trilles; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

9.  Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.

Authors:  Charles E Gast; Luiz R Basso; Igor Bruzual; Brian Wong
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

  9 in total
  6 in total

1.  Resistance Mechanism in a Terbinafine-Resistant Strain of Microsporum canis.

Authors:  Rui Kano; Yun-Hsia Hsiao; Hock Siew Han; Charles Chen; Atsuhiko Hasegawa; Hiroshi Kamata
Journal:  Mycopathologia       Date:  2018-01-16       Impact factor: 2.574

2.  First case of feline cryptococcosis in Hong Kong, caused by Cryptococcus neoformans.

Authors:  Angel Almendros; Daniela H Muguiro; Fraser I Hill; Vanessa R Barrs
Journal:  Med Mycol Case Rep       Date:  2020-05-19

3.  Feline cutaneous nodular and ocular Cryptococcus neoformans in Belgium.

Authors:  Tania C Nunes Rodrigues; Laura R Stroobants; Sophie I Vandenabeele
Journal:  JFMS Open Rep       Date:  2020-04-16

Review 4.  Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens.

Authors:  Katharina Rosam; Brian C Monk; Michaela Lackner
Journal:  J Fungi (Basel)       Date:  2020-12-22

5.  Diagnostic and therapeutic management of Cryptococcosis in a kitten with practical considerations to veterinary pediatric therapeutic approach.

Authors:  Cristina Vercelli; Andrea Peano; Giulia Piovano; Antonio Corona; Graziana Gambino; Giovanni Re
Journal:  Med Mycol Case Rep       Date:  2021-04-13

Review 6.  Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.

Authors:  Thomas R Rogers; Paul E Verweij; Mariana Castanheira; Eric Dannaoui; P Lewis White; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.